SHINE Medical Technologies, a medical isotope manufacturer, announced on Oct. 1 that Todd Asmuth has been named the company’s president.
Asmuth, who has been a SHINE board member for two years, will report to the CEO and dedicate his time on both investor and customer relations as the company gets ready to bring its first product, molybdenum-99, to market.
“SHINE is well-positioned to take the next steps in solving the upcoming shortage of moly-99 and to help the more than 14 million U.S. patients each year who depend on moly-99 for diagnosing and guiding treatment of their illnesses,” Asmuth said in a statement.
“We are thrilled to have an exceptional individual like Todd further strengthen the SHINE team,” Greg Piefer, PhD, founder and CEO of SHINE, said in the same statement. “His focus on investor and customer relations is particularly relevant now as we are achieving key technical and regulatory milestones that allow us to move toward commercial operations.”
Asmuth has previous experience managing four different early-stage ventures and working as a management consultant with Booz Allen Hamilton.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.